Coya Therapeutics vs Entrada Therapeutics
COYA and TRDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How COYA and TRDA compare
Entrada Therapeutics is the larger company, worth 2.7 times as much as Coya Therapeutics ($198M against $73.4M).
Coya Therapeutics grew revenue faster over the last twelve months (17.6% versus −93.5% for Entrada Therapeutics).
Coya Therapeutics keeps more of each dollar of sales as profit, with a net margin of −643% compared with −4058% at Entrada Therapeutics.
Coya Therapeutics scores higher on the StockData Score (7 against 6 for Entrada Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | COYA | TRDA |
|---|---|---|
| Size and price | ||
| Market cap | $73.4M | $198M |
| Share price | $3.13 | $5.09 |
| Change, 1 year | −48.6% | −36.5% |
| Change, 5 years | – | −84.5% |
| Beta (5Y) | 1.19 | 0.96 |
| Employees | 8 | 152 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.7× (better) | 49.8× |
| P/B | 2.2× | 1.0× (better) |
| FCF yield | – | −68.8% |
| Fair value | $2.54 | – |
| Margin of safety | −23.4% | – |
| Growth | ||
| Revenue growth (TTM) | 17.6% (better) | −93.5% |
| Profitability | ||
| Operating margin | −675% (better) | −4304% |
| Net margin | −643% (better) | −4058% |
| FCF margin | – | −3428% |
| Return on equity | −99.2% | −59.9% (better) |
| Return on invested capital | – | −1406% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.24 | 7.85 (better) |
| Altman Z-score | 3.07 (better) | −1.64 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 33.1% | 75.6% |
| Held by insiders | 5.1% | 14.8% |
| Insider net buying, 12 months | – | −$11.5M |
| Short interest, % of float | 6.3% | 8.5% |
Go deeper
- COYA stock overview
- COYA income statement
- COYA valuation and score
- TRDA stock overview
- TRDA income statement
- TRDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.